P95 BV (Ampersand-backed) Merges South Africa CRO OnQ Research into P95
October 16, 2023
P95 BV, a vaccine-focused CRO and portfolio company of Ampersand Capital Partners, has signed an agreement to merge South Africa-based contract research organization OnQ Research into P95. The deal, structured as an add-on to P95, expands P95's presence across Africa and enhances its vaccine and infectious-disease clinical research and real-world evidence capabilities.
- Buyers
- P95 BV, Ampersand Capital Partners
- Targets
- OnQ Research
- Platforms
- P95 BV
- Industry
- Healthcare Services
- Location
- Gauteng, South Africa
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.